CI

At a glance

ClinicalIndex Comparison Record
Phase 1Active· 10 enrolled
Drug / intervention
Methylphenidatedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03814356
NCT03814356Phase 1Active
CompareCT.gov

Stimulant Therapy Targeted to Individualized Connectivity Maps to Promote ReACTivation of Consciousness - A Phase 1 Study

Massachusetts General Hospital·interventional·Posted Jan 24, 2019·Updated Oct 29, 2025

In Brief

A Phase 1 clinical trial evaluating Methylphenidate for Brain Injury Traumatic Severe (Diagnosis) and 3 related conditions. Active but no longer recruiting, targeting 10 participants across 1 site.

Detailed Summary

Phase 1 of the STIMPACT trial is an open label,dose-escalation,safety study of intravenous (IV) methylphenidate (MPH) therapy in patients with disorders of consciousness (DoC) caused by severe brain injuries.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBrain Injury Traumatic Severe (Diagnosis), Coma, Consciousness, Level Altered, Anoxic Brain Injury
CountriesUnited States
CollaboratorsEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Timeline

Phase 1ActiveOverdue
20192020202120222023202420252026
First PostedJan 24, 2019
Enrollment StartAug 24, 2020
Primary CompletionApr 1, 2024
Study CompletionJun 30, 2026
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 7.4 years ago

Interventions

Methylphenidatedrug

IV MPH